A graphite furnace‐atomic absorption spectrometry‐based rubidium efflux assay for screening activators of the Kv7.2/3 channel

Abstract

AbstractFor the characterization of Kv7.2/3 channel activators, several analytical methods are available that vary in effort and cost. In addition to the technically elaborate patch‐clamp method, which serves as a reference method, there exist several medium to high‐throughput screening methods including a rubidium efflux flame‐atomic absorption spectrometry (F‐AAS) assay and a commercial thallium uptake fluorescence‐based assay. In this study, the general suitability of a graphite furnace atomic absorption spectrometry (GF‐AAS)‐based rubidium efflux assay as a screening method for Kv7.2/3 channel activators was demonstrated. With flupirtine serving as a reference compound, 16 newly synthesizedcompounds and the known Kv7.2/3 activator retigabine were first classified as either active or inactive by using the GF‐AAS‐based rubidium (Rb) efflux assay. Then, the results were compared with a thallium (Tl) uptake fluorescence‐based fluorometric imaging plate reader (FLIPR) potassium assay. Overall, 16 of 17 compounds were classified by the GF‐AAS‐based assay in agreement with their channel‐activating properties determined by the more expensive Tl uptake, fluorescence‐based assay. Thus, the performance of the GF‐AAS‐based Rb assay for primary drug screening of Kv7.2/3‐activating compounds was clearly demonstrated, as documented by the calculated Z’‐factor of the GF‐AAS‐based method. Moreover, method development included optimization of the coating of the microtiter plates and the washing procedure, which extended the range of this assay to poorly adherent cells such as the HEK293 cells used in this study.